GSK BOVESPA:G1SK34 주식 보고서 GSK plc
BOVESPA:G1SK34 주식 보고서
G1SK34 주식 개요 GSK plc는 자회사와 함께 영국, 미국 및 전 세계에서 질병 예방 및 치료를 위한 백신, 특수 및 일반 의약품의 연구, 개발 및 제조에 종사하고 있습니다. 자세한 내용
가격 내역 및 성능
다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 GSK 과거 주가 현재 주가 UK£41.08 52주 최고치 UK£50.15 52주 최저치 UK£33.33 베타 0.33 11개월 변경 -6.00% 3개월 변경 사항 -10.15% 1년 변경 사항 20.12% 33년 변화 n/a 5년 변화 n/a IPO 이후 변화 24.22%
최근 뉴스 및 업데이트
GSK plc Announces New Positive Arexvy Data in Younger Adults At Risk Oct 24
GSK plc Announces US Food and Drug Administration Accepts New Drug Application for Treatment of Uncomplicated Urinary Tract Infections in Female Adults and Adolescents Oct 16
GSK plc Announces Positive Headline Results from the Phase III Clinical Trials ANCHOR-1 and ANCHOR-2 Oct 14 Roche/Genentech's Gazyva Poised to Transform Lupus Nephritis Treatment After Positive Phase III Results
GSK plc Presents Positive Data for Arexvy, its Respiratory Syncytial Virus Vaccine Oct 08 Gsk Plc's Menveomeningococcal Vaccine in New Single-Vial, Fully Liquid Presentation Receives Positive European Chmp Opinion Sep 24
더 많은 업데이트 보기
GSK plc Announces New Positive Arexvy Data in Younger Adults At Risk Oct 24
GSK plc Announces US Food and Drug Administration Accepts New Drug Application for Treatment of Uncomplicated Urinary Tract Infections in Female Adults and Adolescents Oct 16
GSK plc Announces Positive Headline Results from the Phase III Clinical Trials ANCHOR-1 and ANCHOR-2 Oct 14 Roche/Genentech's Gazyva Poised to Transform Lupus Nephritis Treatment After Positive Phase III Results
GSK plc Presents Positive Data for Arexvy, its Respiratory Syncytial Virus Vaccine Oct 08 Gsk Plc's Menveomeningococcal Vaccine in New Single-Vial, Fully Liquid Presentation Receives Positive European Chmp Opinion Sep 24
GSK plc Reaches Two Confidential Settlements in Cases Filed in California State Court with John Russell Sep 19
GSK plc Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX Sep 18
GSK plc Announces Positive Headline Results of A Phase Ii Trial (Nct06431607) for Its Mrna Seasonal Influenza Vaccine Programme Sep 13
GSK plc Reaches Confidential Settlement in Zantac Litigation with Isaac Dixon Sep 12
GSK plc Provides Update on Phase I/II Therapeutic Herpes Simplex Virus Vaccine Trial Sep 11
GSK plc Announces European Commission Has Authorised Arexvy for Active Immunisation for the Prevention of Lower Respiratory Tract Disease Aug 29 GSK plc Announces Zantac (Ranitidine) Litigation Update GSK plc Receives US Food and Drug Administration Breakthrough Therapy Designation for GSK5764227 Aug 20
Gsk plc Announces Zantac (Ranitidine) Litigation Update Aug 16
GSK plc Announces Zantac (Ranitidine) Litigation Update Aug 06
GSK plc Announces US FDA Expands Jemperli (Dostarlimab-Gxly) Plus Chemotherapy Approval to All Adult Patients with Primary Advanced or Recurrent Endometrial Cancer as the First and Only Immuno-Oncology-Based Treatment to Show an Overall Survival Benefit Aug 02
GSK plc Declares Second Interim Dividend for Second Quarter of 2024, Payable on 10 October 2024 Jul 31
GSK plc Announces Blenrep EMA Filing Acceptance Jul 22
GSK plc Begins Shipping Influenza Vaccine Doses for 2024-25 Season Jul 12
GSK's Omjjara (Momelotinib) Receives Approval in Japan for Treatment of Myelofibrosis iTeos Therapeutics, Inc. and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer Jun 18
GSK plc Announces That the US Food and Drug Administration (FDA) Has Approved Arexvy Jun 13
GSK plc (LSE:GSK) acquired Elsie Biotechnologies for $50 million. Jun 08 GSK plc Announces Positive Results from an Interim Analysis of the DREAMM-8 Phase III Head-To-Head Trial Evaluating Belantamab Mafodotin Jun 05
GSK plc Provides Litigation Update May 25
An unknown buyer intended to acquire 4.2% stake in Haleon plc (LSE:HLN) from GSK plc (LSE:GSK) for £1.2 billion. May 18
GSK Announces Intention to Sell Approximately 385 Million Shares in Haleon Gsk plc Announces Board Committee Changes May 09
GSK plc to Report Q2, 2024 Results on Jul 31, 2024 May 03 GSK plc Announces the US Food and Drug Administration Accepted the Supplemental Biologics License Application for Jemperli Apr 24
GSK plc Announces Positive Results from the Pivotal Eagle-1 Phase III Trial for Gepotidacin GSK plc Announces US Food and Drug Administration Accepts for Review Biologics License Application for its 5-in-1 Meningococcal ABCWY (MenABCWY) Vaccine Candidate Apr 16
GSK plc, Annual General Meeting, May 08, 2024 Mar 27
GSK plc, Annual General Meeting, May 08, 2024 Mar 26 GSK plc Appoints Hal Dietz as Member of Nominations & Corporate Governance Committee, Effective 11 March 2024 Mar 09
GSK plc Announces Positive Headline Results from an Interim Analysis of the Dreamm-8 Phase Iii Head-To-Head Trial Evaluating Blenrep (Belantamab Mafodotin) Mar 08
GSK plc Reaches a Confidential Settlement with Boyd/Steenvoord GSK plc (LSE:GSK) completed the acquisition of Aiolos Bio, Inc. from a group of shareholders. Feb 15
GSK plc Receives US Food and Drug Administration Fast Track Designation for Bepirovirsen in Chronic Hepatitis B Feb 14
Center for Drug Evaluation Accepts to Review GSK's Regulatory Application for Shingrix for the Prevention of Shingles in at-Risk Adults Aged 18 and over Feb 07 Gsk plc Announces Results from an Interim Analysis of The DREAMM-7 Phase III Head-To-Head Trial
GSK plc to Report Q1, 2024 Results on May 01, 2024 Feb 02
GSK plc Provides an Update on Zantac (Ranitidine) Litigation Feb 01
GSK plc Provides Earnings Guidance for the Year 2024 Jan 31 주주 수익률 G1SK34 BR Pharmaceuticals BR 마켓 7D 0.7% -3.9% -1.9% 1Y 20.1% -15.1% -0.5%
전체 주주 수익률 보기
수익률 대 산업: G1SK34 지난 1년 동안 -15.1 %를 반환한 BR Pharmaceuticals 산업을 초과했습니다.
수익률 대 시장: G1SK34 지난 1년 동안 -0.5 %를 반환한 BR 시장을 초과했습니다.
가격 변동성 Is G1SK34's price volatile compared to industry and market? G1SK34 volatility G1SK34 Average Weekly Movement 4.6% Pharmaceuticals Industry Average Movement 6.6% Market Average Movement 4.5% 10% most volatile stocks in BR Market 8.6% 10% least volatile stocks in BR Market 2.3%
안정적인 주가: G1SK34 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.
시간에 따른 변동성: G1SK34 의 주간 변동성 ( 5% )은 지난 1년 동안 안정적인 모습을 보였습니다.
회사 소개 GSK plc는 자회사와 함께 영국, 미국 및 전 세계에서 질병 예방 및 치료를 위한 백신, 특수 및 일반 의약품의 연구, 개발 및 제조에 종사하고 있습니다. 이 회사는 상업 운영과 종합 R&D의 두 부문으로 운영됩니다. 대상포진, 수막염, 호흡기 세포융합 바이러스, 독감, 소아마비, 인플루엔자 및 팬데믹 백신을 제공합니다.
자세히 보기 GSK plc 기본 사항 요약 GSK 의 수익과 매출은 시가총액과 어떻게 비교하나요? G1SK34 기본 통계 시가총액 R$409.31b 수익(TTM ) R$18.49b 수익(TTM ) R$230.60b
수익 및 수익 최신 수익 보고서의 주요 수익성 통계(TTM) G1SK34 손익 계산서(TTM ) 수익 UK£31.31b 수익 비용 UK£8.65b 총 이익 UK£22.67b 기타 비용 UK£20.15b 수익 UK£2.51b
주당 순이익(EPS) 0.62 총 마진 72.39% 순이익 마진 8.02% 부채/자본 비율 119.4%
G1SK34 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기 예정된 배당금을 받으려면 언제까지 G1SK34 을 구매해야 하나요? GSK 배당 날짜 전 배당일 Nov 13 2024 배당금 지급일 Jan 15 2025 전 배당금까지의 일수 1 day 배당금 지급일까지의 일수 62 days
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
